Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sitamaquine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 2/20 | 0.54 |
| ▸ | CASP6 | P55212 | 2/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitamaquine SCHEMBL29811198 | 0.89 | NSD2 (0.65) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| SCHEMBL14424700 | 0.89 | NSD2 (0.65) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| Sitamaquine SCHEMBL1070741 | 0.89 | NSD2 (0.65) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| Sitamaquine SCHEMBL1230457 | 0.88 | NSD2 (0.64) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| Sitamaquine SCHEMBL1267745 | 0.88 | NSD2 (0.64) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| Sitamaquine SCHEMBL1650398 | 0.88 | NSD2 (0.64) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| SCHEMBL14424702 | 0.85 | NSD2 (0.59) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| SCHEMBL14424685 | 0.82 | NSD2 (0.64) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| SCHEMBL14424692 | 0.82 | NSD2 (0.64) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| SCHEMBL2938115 | 0.80 | NSD2 (0.55) | NSD2CASP6RAD52CASP7HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081906-B1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | claimed |
| US-20100076017-A1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | claimed |
| EP-2081906-A1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | claimed |
| WO-2008043726-A1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| EP-2081906-B1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| EP-2081906-B1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-20100076017-A1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100076017-A1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| EP-2081906-A1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| EP-2081906-A1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008043726-A1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043726-A1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076017-A1 | SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS | SGMS1, GPAA1, SGMS2 | KIT 1804/4885NSD2 935/4885CASP6 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.